Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25348687 | 0.82 | CYP3A4 (0.41) | PPM1BPTPN1PPP1CCALDH1A1CYP2C19 | |
| SCHEMBL7217098 | 0.77 | PPM1B (0.42) | PPM1BPTPN1PPP1CCALDH1A1CYP2C19 | |
| SCHEMBL12219020 | 0.77 | PPM1B (0.42) | PPM1BPTPN1PPP1CCALDH1A1CYP2C19 | |
| SCHEMBL1614134 | 0.76 | PPM1B (0.49) | PPM1BPTPN1PPP1CCALDH1A1LMNA | |
| SCHEMBL28403234 | 0.76 | PPM1B (0.49) | PPM1BPTPN1PPP1CCALDH1A1LMNA | |
| SCHEMBL20489196 | 0.76 | PPM1B (0.49) | PPM1BPTPN1PPP1CCALDH1A1LMNA | |
| SCHEMBL16405665 | 0.76 | PPM1B (0.49) | PPM1BPTPN1PPP1CCALDH1A1LMNA | |
| SCHEMBL15712143 | 0.73 | PPM1B (0.53) | PPM1BPTPN1PPP1CCALDH1A1LMNA | |
| SCHEMBL30148891 | 0.73 | PPM1B (0.39) | PPM1BPTPN1PPP1CCALDH1A1CYP2C19 | |
| SCHEMBL34472936 | 0.73 | PPM1B (0.46) | PPM1BPTPN1PPP1CCALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083599-B1 | PYRAZOLE DERIVATIVES AND USES THEREOF AS INHIBITORS OF DLK | HOFFMANN LA ROCHE (CH) | 2020-07-01 | — | — | EP | disclosed |
| EP-3083599-A1 | PYRAZOLE DERIVATIVES AND USES THEREOF AS INHIBITORS OF DLK | F. Hoffmann-La Roche AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| US-9365583-B2 | Substituted pyrazoles and uses thereof | GENENTECH, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365583-B2 | Substituted pyrazoles and uses thereof | GENENTECH, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365583-B2 | Substituted pyrazoles and uses thereof | GENENTECH, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| WO-2015091889-A1 | PYRAZOLE DERIVATIVES AND USES THEREOF AS INHIBITORS OF DLK | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015091889-A1 | PYRAZOLE DERIVATIVES AND USES THEREOF AS INHIBITORS OF DLK | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| US-20150175619-A1 | SUBSTITUTED PYRAZOLES AND USES THEREOF | GENENTECH, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175619-A1 | SUBSTITUTED PYRAZOLES AND USES THEREOF | GENENTECH, INC. (US) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175619-A1 | SUBSTITUTED PYRAZOLES AND USES THEREOF | PDXK, NLK, PDK3 | PPM1B 2240/4885PTPN1 3670/4885PPP1CC 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.